Cancer Test Market worth US$ 14 Billion by 2018
DALLAS, March 26, 2014 /PRNewswire-iReach/ -- RnRMarketResearch.com adds "Cancer Test Market & Forecast, Companies Cancer Test Platform, Pipeline Analysis and Clinical Trials – Global" to its store that says Cancer testing has tremendous growth opportunities for the next five years.
Cancer is the second-leading cause of death and disability in the world, behind only heart disease. More people die from cancer every year around the world than AIDS, Tuberculosis and Malaria combined. Cancer testing has tremendous growth opportunities for the next five years. According to the National Cancer Institute (NCI), 85% of cancer patients are treated in community-based, private practice oncology settings. Accordingly, global expansion of cancer marker technologies may be fueled by an increased marketing of new diagnostic tests to physicians. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. The anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The global cancer test market is expected to be more than US$ 14 Billion by 2018.
This report provides a comprehensive assessment of the fast-evolving, high-growth of Cancer Test market segment. This 277 page report with 52 Figures and 57 Tables studies the Cancer Test Platform of 20 Companies. This report is broadly divided into 8 chapters.
A. Global – Cancer Testing Market and New Cases (Chapter 2)
B. Global – Cancer Testing Market Share & Forecast (Chapter 3)
C. Global – Segment Wise Cancer Testing Market & Forecast (Chapter 4)
D. Global – Organ Specific Cancer Testing Market & Forecast (Chapter 5)
E. Cancer Diagnostics – Companies Novel Test Platform Analysis (Chapter 6)
F. Geographic Region – Number of New Cancer Cases (Chapter 7)
G. Number of New Cancer Cases by Site – Geographic Region Distribution & Clinical Trials (Chapter 8)
Order a copy of this report at http://www.rnrmarketresearch.com/contacts/purchase?rname=157420 .
Global – Segment Wise Cancer Testing Market (To 2018) (Chapter No. 4)
Prostate Specific Antigen (PSA) Test Market & Forecast
Fecal Occult Blood Test Market & Forecast
Fluorescent In-Situ Hybridization (FISH) Test Market & Forecast
Human Papilloma Virus (HPV) Test Market & Forecast
Bladder Test Market & Forecast
Serum Based Cancer Markers Market & Forecast
Pharmacognostic Histology Market & Forecast
Flow Cytometry Market & Forecast
Other Test Market & Forecast
Global – Organ Specific Cancer Testing Market (To 2018) (Chapter No. 5)
Bladder Cancer Test Market & Forecast
Breast Cancer Test Market & Forecast
Cervical Cancer Test Market & Forecast
Colorectal (Colon) Cancer Test Market & Forecast
Ovarian Cancer Test Market & Forecast
Prostate Cancer Test Market & Forecast
Liver Cancer Test Market & Forecast
Flow Cytometry Market & Forecast
Other Organ Specific Cancer Test Market & Forecast
Comprehensive Table of Contents and more for the report "Cancer Test Market & Forecast, Companies Cancer Test Platform, Pipeline Analysis and Clinical Trials – Global" is available at http://www.rnrmarketresearch.com/cancer-test-market-forecast-companies-cancer-test-platform-pipeline-analysis-and-clinical-trials-global-market-report.html .
Cancer Diagnostics – Companies Novel Test Platform Analysis (Chapter No. 6)
2. Radient Pharmaceuticals
3. BD Diagnostics
4. Beckman Coulter, Inc.
8. CytoCore Inc.
9. DiagnoCure, Inc
10. Gen-Probe, Inc.
11. Genomic Health Inc
12. QIAGEN Marseille (Earlier Ipsogen)
13. Myriad Genetics, Inc
14. Panacea Pharmaceuticals, Inc.
16. Siemens Heathcare Diagnostics
18. Ventana Medical Systems
19. Trovagene Inc
20. Vermillion, Inc
Geographic Region – Number of New Cancer Cases (To 2020) (Chapter No. 7)
Number of New Cancer Cases by Site – Geographic Region Distribution (To 2020) (Chapter 8)
1. Bladder Cancer
2. Brain Cancer
3. Breast Cancer
4. Cervix Cancer
5. Colorectal Cancer
6. Corpus Cancer
7. Hodgkin's Lymphoma
8. Kaposi Sarcoma
9. Kidney Cancer
10. Larynx Cancer
12. Liver Cancer
13. Lung Cancer
17. Non-Hodgkin Lymphoma
19. Oral Cavity
20. Other Pharynx
21. Ovary Cancer
22. Pancreas Cancer
23. Prostate Cancer
24. Stomach Cancer
25. Testis Cancer
26. Thyroid Cancer
27. Other Sites
Cancer Site – Clinical Trials (Chapter 8)
1. Bladder Cancer
2. Cervical Cancer
3. Colorectal Cancer
4. Liver Cancer
5. Ovarian Cancer
6. Prostate Cancer
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Renub Research team of industry experts.
Primary sources include industry surveys and telephone interviews with industry experts.
Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Government Agencies, Magazines, Newspapers, Trade associations, Books, Industry Portals, Industry Associations and access to more than 500 paid databases.
Browse more reports on Cancer Diagnostics market at http://www.rnrmarketresearch.com/reports/life-sciences/diagnostics/in-vitro-diagnostics-ivd/cancer-diagnostics .
Media Contact: Priyank Tiwari, RnR Market Research, + 1 888 391 5441, firstname.lastname@example.org
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE RnR Market Research